Premium
Calcipotriol/betamethasone dipropionate foam demonstrates comparable efficacy to clinical trial data in the real world, improves patient satisfaction and is cost‐effective
Author(s) -
Armstrong A.,
Gerdes S.
Publication year - 2021
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/jdv.17084
Subject(s) - medicine , betamethasone dipropionate , calcipotriol , psoriasis , dermatology , clinical trial , betamethasone , quality of life (healthcare) , randomized controlled trial , patient satisfaction , surgery , nursing
Abstract Real‐world evidence studies are becoming increasingly important in providing insight into clinical effectiveness and safety, economic outcomes, patient‐reported outcomes and health‐related quality of life of treatments in the clinical setting. These studies also help to complement data reported in clinical studies. Fixed‐dose combination calcipotriol 50 µg/g plus betamethasone dipropionate 0.5 mg/g cutaneous foam (Cal/BD foam) is a topical agent used for the treatment of psoriasis vulgaris. In clinical studies, Cal/BD foam has demonstrated a significantly greater efficacy and rapid onset of action compared with both single and combination formulations such as ointments and gels. To date, three observational studies have examined the real‐world efficacy and safety of Cal/BD foam in clinical practice in the United States, Germany and Spain. Data gathered from these studies reinforce the positive findings reported in clinical studies assessing Cal/BD foam for the treatment of psoriasis and demonstrate improved patient satisfaction with Cal/BD foam. Using Cal/BD foam has been shown to be cost‐effective based on results from randomised clinical trials and cost‐effective analysis. As such, Cal/BD foam has the potential to lower treatment costs by reducing the need for some patients to progress to more expensive treatments, such as phototherapy and biologics. Cal/BD foam is therefore a cost‐effective solution for the treatment of psoriasis vulgaris that should be considered when prescribing topicals.